Literature DB >> 14551890

Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism.

Neru Munshi1, Anuradha Balasubramanian, Margaret Koziel, Ramesh K Ganju, Jerome E Groopman.   

Abstract

We hypothesized that hepatocytes exposed to hepatitis C virus (HCV) and human immunodeficiency virus (HIV) might be injured via an "innocent bystander" mechanism due to cell-surface binding of viral proteins. To assess this, we studied the effects of HCV envelope protein E2 and T-tropic HIV envelope glycoprotein gp120 on hepatocytes and saw potent apoptosis. Either viral protein alone did not induce this effect. HCV E2 and M-tropic HIV gp120 also induced significant apoptosis. Blocking the CXCR4 receptor led to a reduction in apoptosis. HCV E2 and HIV gp120 acted collaboratively to trigger a specific set of downstream signaling events, including up-regulation of the Fas ligand and dephosphorylation of the anti-apoptotic molecule AKT. These results suggest that hepatic injury may occur in HCV/HIV coinfection through the induction of novel downstream signaling pathways and provide a rationale for therapeutic interventions that interfere with specific receptors and signaling molecules.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551890     DOI: 10.1086/378643

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

Review 1.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 2.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

3.  Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen.

Authors:  David M Iser; Nadia Warner; Peter A Revill; Ajantha Solomon; Fiona Wightman; Suha Saleh; Megan Crane; Paul U Cameron; Scott Bowden; Tin Nguyen; Cândida F Pereira; Paul V Desmond; Stephen A Locarnini; Sharon R Lewin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

4.  HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity.

Authors:  Nagako Akeno; Jason T Blackard; Yaron Tomer
Journal:  J Autoimmun       Date:  2008-09-16       Impact factor: 7.094

Review 5.  Hepatitis C and interferon induced thyroiditis.

Authors:  Yaron Tomer
Journal:  J Autoimmun       Date:  2010-05       Impact factor: 7.094

6.  Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients.

Authors:  Joseph K Lim; Janet P Tate; Shawn L Fultz; Joseph L Goulet; Joseph Conigliaro; Kendall J Bryant; Adam J Gordon; Cynthia Gibert; David Rimland; Matthew Bidwell Goetz; Marina B Klein; David A Fiellin; Amy C Justice; Vincent Lo Re
Journal:  Clin Infect Dis       Date:  2014-02-25       Impact factor: 9.079

Review 7.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

8.  Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth.

Authors:  Bill G Kapogiannis; Erin Leister; George K Siberry; Russell B Van Dyke; Bret Rudy; Patricia Flynn; Paige L Williams
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

Review 9.  HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?

Authors:  J T Blackard; K E Sherman
Journal:  J Viral Hepat       Date:  2008-01-17       Impact factor: 3.728

10.  HIV induces TRAIL sensitivity in hepatocytes.

Authors:  Challagundla K Babu; Kanitta Suwansrinon; Gary D Bren; Andrew D Badley; Stacey A Rizza
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.